Pre-surgery immunotherapy plus chemo and blood-vessel medicine for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed non-small cell lung cancer that can be removed with surgery (stage II to IIIA).
- Your tumor is not squamous cell cancer, not large-cell cancer, and not sarcomatoid type (and no EGFR mutation).
- You are able to care for yourself and do daily activities (ECOG 0–1).
- Your pre-surgery blood tests and lung function are good enough for an operation.
- You have no autoimmune disease and have not needed immune-suppressing medicines like prednisone for other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests giving chemotherapy followed by the immunotherapy drug sintilimab before surgery for people with EGFR-mutant, early-stage non-small cell lung cancer. It aims to see if this combination reduces the tumor and improves outcomes before surgical removal.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
This study tests a combination of an immunotherapy drug (sintilimab) and chemotherapy to see if it can shrink advanced lung cancer enough to make surgery possible. The goal is to improve outcomes for people whose cancer is currently too extensive for surgery.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
Hear when a new Lung Neoplasm Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.